Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer | List with clinical criteria and/or conditions | Complete | ||
| Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | ||
| XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | |||
| Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
| Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete | ||
| Xolair | Omalizumab | Chronic idiopathic urticaria | List with clinical criteria and/or conditions | Complete | ||
| Xolair | Omalizumab (Drug Plan Submission) | Asthma, severe persistent | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xospata | Gilteritinib | Reimburse with clinical criteria and/or conditions | Complete | |||
| Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | First Line Metastatic Castration-Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xultophy | insulin degludec + liraglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | |||
| Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
| Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
| Yervoy | Ipilimumab | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yervoy | Ipilimumab | First Line Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete |
Last Updated : June 30, 2024